A controversial consensus - comment on article by Broderick et al

Journal of Internal Medicine

Volumn 271, Issue 1, 2012, Pages 29-31

  Van Der Meer, J W M ^a   Lloyd, A R ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

ATAXIA; CHRONIC FATIGUE SYNDROME; COGNITIVE THERAPY; CONSENSUS; DATA COLLECTION METHOD; DISEASE CONTROL; DIZZINESS; EDITORIAL; FATIGUE; GOLD STANDARD; GRAY MATTER; HEALTH CARE; HUMAN; INFLAMMATION; KINESIOTHERAPY; MAJOR DEPRESSION; MENTAL DISEASE; MUSCLE WEAKNESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSOMATIC DISORDER; RETROVIRUS; SCIENTIFIC LITERATURE;

CONSENSUS; FATIGUE SYNDROME, CHRONIC; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES;

EID: 83855164004     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02468.x     Document Type: Editorial

References (37)

1. Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med 2011; 270: 327-38.
2. White PD, Goldsmith KA, Johnson AL et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011; 377: 823-36.
3. Feehan SM. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1831-2.
4. Giakoumakis J. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1831; author reply 4-5.
5. Kewley AJ. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1832; author reply 4-5.
6. Kindlon T. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1833; author reply 4-5.
7. Mitchell JT Jr. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1831; author reply 4-5.
8. Shinohara M. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1833-4; author reply 4-5.
9. Stouten B, Goudsmit EM, Riley N. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1832-3; author reply 4-5.
10. Vlaeyen JW, Karsdorp P, Gatzounis R, Ranson S, Schrooten M. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377: 1834; author reply -5.
11. Prins JB, van der Meer JWM, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006; 367: 346-55.
12. Lombardi VC, Ruscetti FW, Das Gupta J et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009; 326: 585-9.
13. van Kuppeveld FJ, van der Meer JW. XMRV and CFS-the sad end of a story. Lancet 2011; PMID: 21696817.
14. Kaiser J. Chronic fatigue syndrome. Studies point to possible contamination in XMRV findings. Science 2011; 331: 17.
15. van der Meer JWM, Netea MG, Galama JMD, van Kuppeveld FJM. Comment on "Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome". Science 2010; 328: 825; author reply.
16. Sudlow C, Macleod M, Al-Shahi Salman R, Stone J. Comment on "Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome". Science 2010; 328: 825; author reply.
17. McClure M, Wessely S. Chronic fatigue syndrome and human retrovirus XMRV. BMJ 2010; 340: c1099.
18. Lloyd A, White P, Wessely S, Sharpe M, Buchwald D. Comment on "Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome". Science 2010; 328: 825; author reply.
19. Hue S, Gray ER, Gall A et al. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 2010; 7: 111.
20. Erlwein O, Kaye S, McClure MO et al. Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS ONE 2010; 5: e8519.
21. Lloyd AR. Chronic fatigue and chronic fatigue syndrome: shifting boundaries and attributions. Am J Med 1998; 105: 7S-10S.
22. Kennedy G, Abbot NC, Spence V, Underwood C, Belch JJF. The specificity of the CDC-1994 criteria for chronic fatigue syndrome: comparison of health status in three groups of patients who fulfill the criteria. Ann Epidemiol 2004; 14: 95-100.
23. Jason LA, Helgerson J, Torres-Harding SR, Carrico AW, Taylor RR. Variability in diagnostic criteria for chronic fatigue syndrome may result in substantial differences in patterns of symptoms and disability. Eval Health Prof 2003; 26: 3-22.
24. Hickie I, Davenport T, Vernon SD et al. Are chronic fatigue and chronic fatigue syndrome valid clinical entities across countries and healthcare settings? Aust N Z J Psychiatry 2009; 43: 25-35.
25. Lin JM, Brimmer DJ, Maloney EM, Nyarko E, Belue R, Reeves WC. Further validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul Health Metr 2009; 7: 18.
26. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953-9.
27. Jason LA, Taylor RR, Plioplys S, Stepanek Z, Shlaes J. Evaluating attributions for an illness based upon the name: chronic fatigue syndrome, myalgic encephalopathy and Florence Nightingale disease. Am J Community Psychol 2002; 30: 133-48.
28. Lyall M, Peakman M, Wessely S. A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res 2003; 55: 79-90.
29. McKenzie R, O'Fallon A, Dale J et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 1998; 280: 1061-6.
30. Baschetti R. Investigations of hydrocortisone and fludrocortisone in the treatment of chronic fatigue syndrome. J Clin Endocrinol Metab 1999; 84: 2263-4.
31. Cleare AJ, Miell J, Heap E et al. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab 2001; 86: 3545-54.
32. Blockmans D, Persoons P, Van Houdenhove B, Lejeune M, Bobbaers H. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study. Am J Med 2003; 114: 736-41.
33. Reeves WC, Lloyd A, Vernon SD et al. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res 2003; 3: 25.
34. de Lange FP, Kalkman JS, Bleijenberg G, Hagoort P, van der Meer JWM, Toni I. Gray matter volume reduction in the chronic fatigue syndrome. Neuroimage 2005; 26: 777-81.
35. Cho HJ, Skowera A, Cleare A, Wessely S. Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology. Curr Opin Psychiatry 2006; 19: 67-73.
36. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003; 160: 221-36.
37. Wilson A, Hickie I, Hadzi-Pavlovic D et al. What is chronic fatigue syndrome? Heterogeneity within an international multicentre study Aust N Z J Psychiatry 2001; 35: 520-7.